Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
221 Crescent Street, Building 23, Suite 105, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aeglea BioTherapeutics, Inc. (to 11/24/2023)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.11K % +328%
Debt-to-equity 23.9 %
Return On Equity -60.7 % -111%
Return On Assets -42.6 % +73.4%
Operating Margin -39.4K % -480%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.3M shares +49.6%
Common Stock, Shares, Outstanding 60.3M shares +67.1%
Entity Public Float 1.1B USD +4098%
Common Stock, Value, Issued 13K USD +30%
Weighted Average Number of Shares Outstanding, Basic 50.9M shares +1085%
Weighted Average Number of Shares Outstanding, Diluted 50.9M shares +1085%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 55.4M USD -11%
General and Administrative Expense 45.8M USD +14.6%
Operating Income (Loss) -209M USD +13.9%
Nonoperating Income (Expense) 599K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -208M USD +38.6%
Income Tax Expense (Benefit) 51K USD
Net Income (Loss) Attributable to Parent -208M USD +38.6%
Earnings Per Share, Basic -20 USD/shares -219%
Earnings Per Share, Diluted -20 USD/shares -219%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 89.4M USD -52.7%
Cash, Cash Equivalents, and Short-term Investments 603M USD +77.7%
Assets, Current 608M USD +78.2%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 10K USD +11.1%
Assets 608M USD +78%
Accounts Payable, Current 2.85M USD +45.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 54.1M USD +69.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 90.7M USD +23.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 180K USD -40.4%
Retained Earnings (Accumulated Deficit) -972M USD -27.2%
Stockholders' Equity Attributable to Parent 518M USD +181%
Liabilities and Equity 608M USD +78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.5M USD -61.9%
Net Cash Provided by (Used in) Financing Activities 172M USD
Net Cash Provided by (Used in) Investing Activities -105M USD -691%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 60.3M shares +67.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 38.7M USD +28116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 89.4M USD -52.7%
Deferred Tax Assets, Valuation Allowance 163M USD +29.8%
Deferred Tax Assets, Gross 163M USD +29.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -208M USD +38.5%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -104%
Deferred Tax Assets, Operating Loss Carryforwards 87.3M USD +17.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +14.1%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Share-based Payment Arrangement, Expense 13.1M USD +174%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%